Pharmaceuticals News and Research

RSS

Zabecor Pharmaceuticals initiates Phase II clinical trial of its Excellair asthma drug

ZaBeCor Pharmaceuticals ("ZaBeCor" or the "Company") announced today the initiation of a Phase II clinical trial for its asthma drug candidate Excellair™, following the successful results of the Company's Phase I clinical trials. ZaBeCor is one of the first companies to deliver siRNA to the lung and one of the first to target asthma with siRNA.

14 Sep 2009

Comparative effectiveness research may save money, but remains controversial

The Louisville Courier-Journal reports: "Democrats' plans for health care reform would try to provide answers with more studies on which drugs, medical devices and procedures work best for different patients. But while the goal of more 'comparative effectiveness' research may sound simple, getting there may be a challenge."

14 Sep 2009

Systech International announces new software for SPT application

Systech International, innovator of Packaging Execution Systems (PES) for the pharmaceutical industry, today announced the availability of a new software release for its widely-deployed Serialized Product Tracking (SPT) application.

14 Sep 2009

Career GPS program to help displaced biopharmaceutical professionals

BioAdvance, the University City Science Center and Wharton Small Business Development Center (SBDC) are collaborating to develop Career GPS, a program which is designed to help displaced biopharmaceutical professionals navigate the Greater Philadelphia region’s entrepreneurial career eco-system.

14 Sep 2009

IVIS Lumina XR in vivo imaging system from Caliper Life Sciences

Caliper Life Sciences, Inc., a leading provider of tools and services for drug discovery and life sciences research, today introduced the IVIS Lumina XR in vivo imaging system, the latest addition to the IVIS product family.

14 Sep 2009

Internet marketing program from AVVH

avVaa World Health Care Products Inc. (Pink Sheets: AVVH), a global biotechnology company, manufacturer and distributor of nationally branded therapeutic, natural skin and health care products, announced today the launch of a major Internet marketing program.

14 Sep 2009

Spinal implants market to grow in the coming years: iData Research

According to a new market research report by iData Research, the leading international authority in medical device, dental and pharmaceutical market research, the U.S. market for spinal motion preservation devices is estimated to reach $2.54 billion by 2015. The global market for minimally invasive surgery (MIS) is also estimated to see double digit growth, with these two segments driving the overall market for spinal implants, MIS and VCF devices.

14 Sep 2009

Phase 1 results of CTP-347 presented

Concert Pharmaceuticals, Inc. announced today the presentation of Phase 1 data on CTP-347, a deuterium-modified analog of paroxetine for the treatment of hot flashes. Concert presented the results during a poster session at the American College of Clinical Pharmacology’s 38th Annual Meeting.

14 Sep 2009

Sunlight Research's report analyzes Amgen EPO US patent portfolio

Sunlight Research((TM)) - The Source for Patent Analysis today announced the release of its report analyzing Amgen, Inc.'s Erythropoietin (EPO) US patent portfolio.

14 Sep 2009

Preliminary results of Phase 2b clinical trial of AZ-104 announced by Alexza Pharmaceuticals

Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced preliminary results from its 366 patient Phase 2b clinical trial of AZ-104 (Staccato(R) loxapine) in patients with migraine headache.

14 Sep 2009

Patheon declares third quarter 2009 results

Patheon (TSX: PTI) today announced results for the third quarter and nine months ended July 31, 2009. Total revenues for the third quarter were $164.4 million or 15.7% lower than the same period last year. Excluding currency fluctuations, current year third quarter revenues would have decreased by approximately 9.6%.

14 Sep 2009

ARIAD to complete its Phase 3 SUCCEED trial following DMS recommendation

ARIAD Pharmaceuticals, Inc. (NASDAQ:ARIA) today announced that the independent Data Monitoring Committee (DMC) of the Phase 3 SUCCEED trial has completed the first interim efficacy analysis as specified by the study protocol and has recommended that the randomized, placebo-controlled trial of oral ridaforolimus in patients with metastatic sarcomas continue to full patient enrollment and completion.

14 Sep 2009

Gen-Probe to merge industrial testing assets into an independent company

Gen-Probe Incorporated announced today that it is spinning off its industrial testing assets into a new, independent company focused on developing rapid, highly accurate molecular assays for biopharmaceutical production, water and food safety testing, and other applications.

14 Sep 2009

DSG’s eCaseLink EDC software used in Cipher's Phase 3 dermatology study

DSG Inc., an industry leader in clinical trial data collection and management, today announced that Cipher Pharmaceuticals (TSX:DND) is using electronic data capture (EDC) software and data management services from DSG. Cipher is using DSG’s eCaseLink™ for its Phase 3 dermatology study on its new compound for the treatment of severe acne.

14 Sep 2009

CDI and VivoMedica launch pharmaceutical industry consortium

Cellular Dynamics International (CDI) and VivoMedica plc announce the launch of CARDIOTOX - a pharmaceutical industry consortium to validate a human cell model and analysis system for preclinical cardiotoxicity testing of pharmaceutical candidate compounds.

14 Sep 2009

Millipore and Roka Bioscience collaborate for developing molecular assays

Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that it will collaborate with Roka Bioscience, Inc. to develop molecular assays and portable instruments for biopharmaceutical production.

14 Sep 2009

Patient enrollment for Phase 3 clinical trials of VEGF Trap-Eye completed

Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced the completion of patient enrollment in two randomized, double-masked, Phase 3 clinical trials evaluating VEGF Trap-Eye in the treatment of the neovascular form of age-related macular degeneration (wet AMD).

14 Sep 2009

Mylan Pharmaceutical's ANDA for Teva's Copaxone accepted by FDA (Correction)

Mylan Inc. (Nasdaq: MYL) today announced that the U.S. Food and Drug Administration (FDA) has accepted for filing Mylan Pharmaceutical Inc.'s abbreviated new drug application (ANDA) for Glatiramer Acetate Injection (20 mg/mL), a generic version of Teva's Copaxone(R), a product indicated for the treatment of multiple sclerosis.

14 Sep 2009

TYRX to exhibit AIGISRx Anti-Bacterial Envelope at HFSA

TYRX, Inc., a leader in the commercialization of implantable medical-pharmaceutical devices, announced today that it will be exhibiting its lead product, AIGISRx Anti-Bacterial Envelope, at the 13th Annual Heart Failure Society of America Meeting (HFSA), in Boston, MA this week.

14 Sep 2009

Prolifiq's sales communication software for Life Sciences companies

Today at the annual RAPS (Regulatory Affairs Professionals Society) conference in booth #607, Prolifiq announced software that allows Life Sciences companies to comply with an increasingly complex web of regulations governing sales communication. Prolifiq for Life Sciences--designed for medical device, pharmaceutical and biotechnology companies--is used to organize, send and track approved digital content to health care practitioners.

14 Sep 2009